What Is Antiretroviral Therapy (ART)?
July 29, 2013
ART means treating retroviral infections like HIV with drugs. The drugs do not kill the virus. However, they slow down the growth of the virus. When the virus is slowed down, so is HIV disease. Antiretroviral drugs are referred to as ARV. ARV therapy is referred to as ART or CART (Combination Antiretroviral Therapy.)
Fact Sheet 106 for a diagram.)
Each type, or "class", of ARV drugs attacks HIV in a different way. The first class of anti-HIV drugs was the nucleoside reverse transcriptase inhibitors (also called NRTIs or "nukes".) These drugs block step 4, where the HIV genetic material is used to create DNA from RNA. The following drugs in this class are used:
Non-nucleoside reverse transcriptase inhibitors, also called non-nukes or NNRTIs, also block step 4 but in a different way. Five have been approved:
Protease inhibitors or PIs block Step 10, where the raw material for new HIV virus is cut into specific pieces. Ten protease inhibitors are approved:
Entry inhibitors prevent HIV from entering a cell by blocking step 2 of the life cycle. Two drugs of this type have been approved:
HIV integrase inhibitors prevent HIV from inserting its genetic code into the human cell's code in step 5 of the life cycle. The two drugs of this type are:
Antiretroviral drugs are usually used in combinations of three or more drugs from more than one class. This is called "Combination Therapy." Combination therapy works better than using just one ARV alone, It also helps prevent drug resistance.
Manufacturers of ARVs keep trying to make their drugs easier to take, and have combined some of them into a single pill. See Fact Sheet 409 for more information on combination medications.
When HIV multiplies, most of the new copies are mutations: they are slightly different from the original virus. Some mutations keep multiplying even when you are taking an ARV drugs. When this happens, the drug will stop working. This is called "developing resistance" to the drug. See Fact Sheet 126 for more information.
If only one ARV drug is used, it is easy for the virus to develop resistance. For this reason, using just one or two drugs is not recommended. But if two or three drugs are used, a successful mutant would have to "get around" all of the drugs at the same time. Using combination therapy means that it takes much longer for resistance to develop.
ARVs reduce the "viral load", the amount of virus in your bloodstream, but are not a cure. A blood test measures the viral load. People with lower viral loads stay healthier longer.
Some people's viral load is so low that it is "undetectable" by the viral load test. This does not mean that all the virus is gone and it does not mean a person is cured of HIV infection. See Fact Sheet 125 for more information on viral load.
There is not a clear answer to this question. Most doctors will consider your CD4 cell count and any symptoms you've had. Current US guidelines say that everyone who is infected with HIV should start ARV therapy. See Fact Sheet 404 for more information on treatment guidelines. This is an important decision you should discuss with your health care provider.
ARV drugs are chosen on the basis of HIV drug resistance, your health (for example, kidney or liver disease) and lifestyle factors. While ARV regimens are usually well tolerated, each ARV drug can have side effects. Some may be serious. Refer to the fact sheet for each individual drug. Each person is different, and you and your health care provider will have to decide which drugs to use.
Adherence to ARVs is very important for treatment to work. The viral load test is used to see if ARV drugs are working.
New drugs are being studied in all of the existing classes. Researchers are also trying to develop new types of drugs, such as drugs that will block other steps in the HIV life cycle, and drugs that will strengthen the body's immune defenses. See Fact Sheets 470 and 480 for more information on newer classes of drugs.
This article was provided by AIDS InfoNet. Visit AIDS InfoNet's website to find out more about their activities and publications.